Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines

Full text
Author(s):
de Oliveira, Mariana B. [1] ; Sanson, Luiz F. G. [1] ; Eugenio, Angela I. P. [1] ; Barbosa-Dantas, Rebecca S. S. [1] ; Colleoni, Gisele W. B. [1]
Total Authors: 5
Affiliation:
[1] Univ Fed Sao Paulo, UNIFESP, Clin & Expt Oncol Dept, Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: CURRENT MOLECULAR MEDICINE; v. 19, n. 2, p. 112-119, 2019.
Web of Science Citations: 0
Abstract

Introduction: Multiple myeloma (MM) cells accumulate in the bone marrow and produce enormous quantities of immunoglobulins, causing endoplasmatic reticulum stress and activation of protein handling machinery, such as heat shock protein response, autophagy and unfolded protein response (UPR). Methods: We evaluated cell lines viability after treatment with bortezomib (B) in combination with HSP70 (VER-15508) and autophagy (SBI-0206965) or UPR (STF-083010) inhibitors. Results: For RPMI-8226, after 72 hours of treatment with B+VER+STF or B+VER+SBI, we observed 15% of viable cells, but treatment with B alone was better (90% of cell death). For U266, treatment with B+VER+STF or with B+VER+SBI for 72 hours resulted in 20% of cell viability and both treatments were better than treatment with B alone (40% of cell death). After both triplet combinations, RPMI-8226 and U266 presented the overexpression of XBP-1 UPR protein, suggesting that it is acting as a compensatory mechanism, in an attempt of the cell to handle the otherwise lethal large amount of immunoglobulin overload. Conclusion: Our in vitro results provide additional evidence that combinations of protein homeostasis inhibitors might be explored as treatment options for MM. (AU)

FAPESP's process: 10/17668-6 - Identification of biomarkers and possible therapeutical targets in B-cell lymphoproliferative disorders
Grantee:Gisele Wally Braga Colleoni
Support type: Research Projects - Thematic Grants